ES2610185T3 - Composición farmacéutica - Google Patents
Composición farmacéutica Download PDFInfo
- Publication number
- ES2610185T3 ES2610185T3 ES11760631.9T ES11760631T ES2610185T3 ES 2610185 T3 ES2610185 T3 ES 2610185T3 ES 11760631 T ES11760631 T ES 11760631T ES 2610185 T3 ES2610185 T3 ES 2610185T3
- Authority
- ES
- Spain
- Prior art keywords
- methyl
- pyrazol
- nmr
- mhz
- ppm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 50
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 34
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 22
- 150000002431 hydrogen Chemical group 0.000 claims abstract 15
- 239000001257 hydrogen Substances 0.000 claims abstract 15
- 229910052736 halogen Inorganic materials 0.000 claims abstract 12
- 150000002367 halogens Chemical group 0.000 claims abstract 12
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract 12
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims abstract 9
- 150000003839 salts Chemical class 0.000 claims abstract 9
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 claims abstract 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims abstract 3
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 3
- 239000001301 oxygen Substances 0.000 claims abstract 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 100
- 238000005160 1H NMR spectroscopy Methods 0.000 description 61
- 238000004519 manufacturing process Methods 0.000 description 44
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 29
- 238000000034 method Methods 0.000 description 24
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 18
- 102100024450 Prostaglandin E2 receptor EP4 subtype Human genes 0.000 description 16
- SZRSMNYUEXXEBL-UHFFFAOYSA-N 5-chloro-1,3-dimethylpyrazole-4-carbaldehyde Chemical compound CC1=NN(C)C(Cl)=C1C=O SZRSMNYUEXXEBL-UHFFFAOYSA-N 0.000 description 15
- 229960002986 dinoprostone Drugs 0.000 description 14
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 13
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 206010003246 arthritis Diseases 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 101150109738 Ptger4 gene Proteins 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- SZUAJCIGBDCCPA-UHFFFAOYSA-N [1-(4-methoxycarbonylphenyl)cyclopropyl]azanium;chloride Chemical compound [Cl-].C1=CC(C(=O)OC)=CC=C1C1([NH3+])CC1 SZUAJCIGBDCCPA-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- XOTRLVYRAWIVLC-FJXQXJEOSA-N methyl 4-[(1s)-1-aminoethyl]benzoate;hydrochloride Chemical compound [Cl-].COC(=O)C1=CC=C([C@H](C)[NH3+])C=C1 XOTRLVYRAWIVLC-FJXQXJEOSA-N 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000009739 binding Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 208000009386 Experimental Arthritis Diseases 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 102000013691 Interleukin-17 Human genes 0.000 description 5
- 108050003558 Interleukin-17 Proteins 0.000 description 5
- 108010065637 Interleukin-23 Proteins 0.000 description 5
- 102000013264 Interleukin-23 Human genes 0.000 description 5
- 241000219061 Rheum Species 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- JYOWJKUJOVHUFH-UHFFFAOYSA-N 4-(1-aminocyclopropyl)benzoic acid Chemical compound C=1C=C(C(O)=O)C=CC=1C1(N)CC1 JYOWJKUJOVHUFH-UHFFFAOYSA-N 0.000 description 4
- NMYPMEAFQUDCSC-UHFFFAOYSA-N 5-chloro-3-(difluoromethyl)-1-methylpyrazole-4-carbaldehyde Chemical compound CN1N=C(C(F)F)C(C=O)=C1Cl NMYPMEAFQUDCSC-UHFFFAOYSA-N 0.000 description 4
- -1 7-azabenzotriazol-1-yl Chemical group 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- 101000713602 Homo sapiens T-box transcription factor TBX21 Proteins 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 102100036840 T-box transcription factor TBX21 Human genes 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical group COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 description 4
- 150000004702 methyl esters Chemical class 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000002287 radioligand Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- YRZBQWXCNGHQKH-UHFFFAOYSA-N 1-methyl-3-(trifluoromethyl)-5-[4-(trifluoromethyl)phenoxy]pyrazole-4-carboxylic acid Chemical compound CN1N=C(C(F)(F)F)C(C(O)=O)=C1OC1=CC=C(C(F)(F)F)C=C1 YRZBQWXCNGHQKH-UHFFFAOYSA-N 0.000 description 3
- CTNOWZKNZZFOFF-UHFFFAOYSA-N 5-(3-chlorophenoxy)-1-methyl-3-(trifluoromethyl)pyrazole-4-carboxylic acid Chemical compound CN1N=C(C(F)(F)F)C(C(O)=O)=C1OC1=CC=CC(Cl)=C1 CTNOWZKNZZFOFF-UHFFFAOYSA-N 0.000 description 3
- PZOZNOVIRZSNHJ-UHFFFAOYSA-N 5-chloro-1-methyl-3-(trifluoromethyl)pyrazole-4-carbaldehyde Chemical compound CN1N=C(C(F)(F)F)C(C=O)=C1Cl PZOZNOVIRZSNHJ-UHFFFAOYSA-N 0.000 description 3
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 3
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 101710114878 Phospholipase A-2-activating protein Proteins 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- BLFWHYXWBKKRHI-JYBILGDPSA-N plap Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](N)CCC(O)=O BLFWHYXWBKKRHI-JYBILGDPSA-N 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000001525 receptor binding assay Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- DBGCRJGHJPMILT-UHFFFAOYSA-N 1,3-dimethyl-5-(4-methylphenoxy)pyrazole-4-carboxylic acid Chemical compound CC1=NN(C)C(OC=2C=CC(C)=CC=2)=C1C(O)=O DBGCRJGHJPMILT-UHFFFAOYSA-N 0.000 description 2
- PXLDNTZHJFLCCC-UHFFFAOYSA-N 1,3-dimethyl-5-[3-(trifluoromethyl)phenoxy]pyrazole-4-carboxylic acid Chemical compound CC1=NN(C)C(OC=2C=C(C=CC=2)C(F)(F)F)=C1C(O)=O PXLDNTZHJFLCCC-UHFFFAOYSA-N 0.000 description 2
- VGTGQSZJFZSRTL-UHFFFAOYSA-N 1-methyl-3-(trifluoromethyl)-5-[3-(trifluoromethyl)phenoxy]pyrazole-4-carboxylic acid Chemical compound CN1N=C(C(F)(F)F)C(C(O)=O)=C1OC1=CC=CC(C(F)(F)F)=C1 VGTGQSZJFZSRTL-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- XQDNFAMOIPNVES-UHFFFAOYSA-N 3,5-Dimethoxyphenol Chemical compound COC1=CC(O)=CC(OC)=C1 XQDNFAMOIPNVES-UHFFFAOYSA-N 0.000 description 2
- TUAMRELNJMMDMT-UHFFFAOYSA-N 3,5-xylenol Chemical compound CC1=CC(C)=CC(O)=C1 TUAMRELNJMMDMT-UHFFFAOYSA-N 0.000 description 2
- LBIKGXKZGDEMPM-UHFFFAOYSA-N 3-(difluoromethyl)-1-methyl-5-[4-(trifluoromethyl)phenoxy]pyrazole-4-carboxylic acid Chemical compound CN1N=C(C(F)F)C(C(O)=O)=C1OC1=CC=C(C(F)(F)F)C=C1 LBIKGXKZGDEMPM-UHFFFAOYSA-N 0.000 description 2
- HORNXRXVQWOLPJ-UHFFFAOYSA-N 3-chlorophenol Chemical compound OC1=CC=CC(Cl)=C1 HORNXRXVQWOLPJ-UHFFFAOYSA-N 0.000 description 2
- BAYGVMXZJBFEMB-UHFFFAOYSA-N 4-(trifluoromethyl)phenol Chemical compound OC1=CC=C(C(F)(F)F)C=C1 BAYGVMXZJBFEMB-UHFFFAOYSA-N 0.000 description 2
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- JBIGAVFKJVBCEI-UHFFFAOYSA-N 5-(3,4-dichlorophenoxy)-3-(difluoromethyl)-1-methylpyrazole-4-carboxylic acid Chemical compound CN1N=C(C(F)F)C(C(O)=O)=C1OC1=CC=C(Cl)C(Cl)=C1 JBIGAVFKJVBCEI-UHFFFAOYSA-N 0.000 description 2
- GAIQDWXMEFAMGH-UHFFFAOYSA-N 5-(3-chlorophenoxy)-3-(difluoromethyl)-1-methylpyrazole-4-carboxylic acid Chemical compound CN1N=C(C(F)F)C(C(O)=O)=C1OC1=CC=CC(Cl)=C1 GAIQDWXMEFAMGH-UHFFFAOYSA-N 0.000 description 2
- HTJWLXOHCXEICH-UHFFFAOYSA-N 5-(4-chlorophenoxy)-1-methyl-3-(trifluoromethyl)pyrazole-4-carboxylic acid Chemical compound CN1N=C(C(F)(F)F)C(C(O)=O)=C1OC1=CC=C(Cl)C=C1 HTJWLXOHCXEICH-UHFFFAOYSA-N 0.000 description 2
- YVMRWDBFRHLFBX-UHFFFAOYSA-N 5-(4-chlorophenoxy)-3-(difluoromethyl)-1-methylpyrazole-4-carboxylic acid Chemical compound CN1N=C(C(F)F)C(C(O)=O)=C1OC1=CC=C(Cl)C=C1 YVMRWDBFRHLFBX-UHFFFAOYSA-N 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 101001044908 Cairina moschata Chymotrypsin inhibitor Proteins 0.000 description 2
- 102000000503 Collagen Type II Human genes 0.000 description 2
- 108010041390 Collagen Type II Proteins 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010065390 Inflammatory pain Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000008866 Prostaglandin E receptors Human genes 0.000 description 2
- 108010088540 Prostaglandin E receptors Proteins 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229940124829 interleukin-23 Drugs 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 102000017953 prostanoid receptors Human genes 0.000 description 2
- 108050007059 prostanoid receptors Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- UUANPFSBYRYRCO-UHFFFAOYSA-N 1,3-dimethyl-5-(3-methylphenoxy)pyrazole-4-carboxylic acid Chemical compound CC1=NN(C)C(OC=2C=C(C)C=CC=2)=C1C(O)=O UUANPFSBYRYRCO-UHFFFAOYSA-N 0.000 description 1
- IJIXFOSIBZHPCV-UHFFFAOYSA-N 1,3-dimethyl-5-[3-(trifluoromethoxy)phenoxy]pyrazole-4-carboxylic acid Chemical compound CC1=NN(C)C(OC=2C=C(OC(F)(F)F)C=CC=2)=C1C(O)=O IJIXFOSIBZHPCV-UHFFFAOYSA-N 0.000 description 1
- DUPHOICPOFZVLW-UHFFFAOYSA-N 1,3-dimethyl-5-[4-(trifluoromethyl)phenoxy]pyrazole-4-carboxylic acid Chemical compound CC1=NN(C)C(OC=2C=CC(=CC=2)C(F)(F)F)=C1C(O)=O DUPHOICPOFZVLW-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- UMPSXRYVXUPCOS-UHFFFAOYSA-N 2,3-dichlorophenol Chemical compound OC1=CC=CC(Cl)=C1Cl UMPSXRYVXUPCOS-UHFFFAOYSA-N 0.000 description 1
- RPEPGIOVXBBUMJ-UHFFFAOYSA-N 2,3-difluorophenol Chemical compound OC1=CC=CC(F)=C1F RPEPGIOVXBBUMJ-UHFFFAOYSA-N 0.000 description 1
- INXKVYFOWNAVMU-UHFFFAOYSA-N 2,5-difluorophenol Chemical compound OC1=CC(F)=CC=C1F INXKVYFOWNAVMU-UHFFFAOYSA-N 0.000 description 1
- IGYXYGDEYHNFFT-UHFFFAOYSA-N 2-chloro-4-fluorophenol Chemical compound OC1=CC=C(F)C=C1Cl IGYXYGDEYHNFFT-UHFFFAOYSA-N 0.000 description 1
- CMQOZIKIOASEIN-UHFFFAOYSA-N 2-chloro-5-fluorophenol Chemical compound OC1=CC(F)=CC=C1Cl CMQOZIKIOASEIN-UHFFFAOYSA-N 0.000 description 1
- VPOMSPZBQMDLTM-UHFFFAOYSA-N 3,5-dichlorophenol Chemical compound OC1=CC(Cl)=CC(Cl)=C1 VPOMSPZBQMDLTM-UHFFFAOYSA-N 0.000 description 1
- HJSSBIMVTMYKPD-UHFFFAOYSA-N 3,5-difluorophenol Chemical compound OC1=CC(F)=CC(F)=C1 HJSSBIMVTMYKPD-UHFFFAOYSA-N 0.000 description 1
- UWLJERQTLRORJN-UHFFFAOYSA-N 3-(trifluoromethoxy)phenol Chemical compound OC1=CC=CC(OC(F)(F)F)=C1 UWLJERQTLRORJN-UHFFFAOYSA-N 0.000 description 1
- UGEJOEBBMPOJMT-UHFFFAOYSA-N 3-(trifluoromethyl)phenol Chemical compound OC1=CC=CC(C(F)(F)F)=C1 UGEJOEBBMPOJMT-UHFFFAOYSA-N 0.000 description 1
- ZMFBYTAAMHWQHD-UHFFFAOYSA-N 3-chloro-5-fluorophenol Chemical compound OC1=CC(F)=CC(Cl)=C1 ZMFBYTAAMHWQHD-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- MKLKAQMPKHNQPR-NSHDSACASA-N 4-[(1s)-1-[[3-(difluoromethyl)-1-methyl-5-[3-(trifluoromethyl)phenoxy]pyrazole-4-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C=1C(C(F)F)=NN(C)C=1OC1=CC=CC(C(F)(F)F)=C1 MKLKAQMPKHNQPR-NSHDSACASA-N 0.000 description 1
- YDEHGSIKDFSJOR-UHFFFAOYSA-N 5-(2,3-dichlorophenoxy)-1,3-dimethylpyrazole-4-carboxylic acid Chemical compound CC1=NN(C)C(OC=2C(=C(Cl)C=CC=2)Cl)=C1C(O)=O YDEHGSIKDFSJOR-UHFFFAOYSA-N 0.000 description 1
- LNCGHIFRZWTAGJ-UHFFFAOYSA-N 5-(2,3-difluorophenoxy)-1,3-dimethylpyrazole-4-carboxylic acid Chemical compound CC1=NN(C)C(OC=2C(=C(F)C=CC=2)F)=C1C(O)=O LNCGHIFRZWTAGJ-UHFFFAOYSA-N 0.000 description 1
- KHDKCGHGZOZAPJ-UHFFFAOYSA-N 5-(2,5-difluorophenoxy)-1,3-dimethylpyrazole-4-carboxylic acid Chemical compound CC1=NN(C)C(OC=2C(=CC=C(F)C=2)F)=C1C(O)=O KHDKCGHGZOZAPJ-UHFFFAOYSA-N 0.000 description 1
- UMPGIHXLKBQSET-UHFFFAOYSA-N 5-(2-chloro-4-fluorophenoxy)-1,3-dimethylpyrazole-4-carboxylic acid Chemical compound CC1=NN(C)C(OC=2C(=CC(F)=CC=2)Cl)=C1C(O)=O UMPGIHXLKBQSET-UHFFFAOYSA-N 0.000 description 1
- UIFDWVFVPUSBNF-UHFFFAOYSA-N 5-(2-chloro-5-fluorophenoxy)-1,3-dimethylpyrazole-4-carboxylic acid Chemical compound CC1=NN(C)C(OC=2C(=CC=C(F)C=2)Cl)=C1C(O)=O UIFDWVFVPUSBNF-UHFFFAOYSA-N 0.000 description 1
- JNFVDVNTXYAHJT-UHFFFAOYSA-N 5-(3,4-dichlorophenoxy)-1-methyl-3-(trifluoromethyl)pyrazole-4-carboxylic acid Chemical compound CN1N=C(C(F)(F)F)C(C(O)=O)=C1OC1=CC=C(Cl)C(Cl)=C1 JNFVDVNTXYAHJT-UHFFFAOYSA-N 0.000 description 1
- MDZFWFPWKCNFFN-UHFFFAOYSA-N 5-(3,4-difluorophenoxy)-1,3-dimethylpyrazole-4-carboxylic acid Chemical compound CC1=NN(C)C(OC=2C=C(F)C(F)=CC=2)=C1C(O)=O MDZFWFPWKCNFFN-UHFFFAOYSA-N 0.000 description 1
- SYBGBOHOCFPOBF-UHFFFAOYSA-N 5-(3,5-dichlorophenoxy)-1,3-dimethylpyrazole-4-carboxylic acid Chemical compound CC1=NN(C)C(OC=2C=C(Cl)C=C(Cl)C=2)=C1C(O)=O SYBGBOHOCFPOBF-UHFFFAOYSA-N 0.000 description 1
- WZVWLPXMLZKITO-UHFFFAOYSA-N 5-(3,5-dimethoxyphenoxy)-1,3-dimethylpyrazole-4-carboxylic acid Chemical compound COC1=CC(OC)=CC(OC=2N(N=C(C)C=2C(O)=O)C)=C1 WZVWLPXMLZKITO-UHFFFAOYSA-N 0.000 description 1
- HYDZFUQIPPQKIR-UHFFFAOYSA-N 5-(3,5-dimethylphenoxy)-1,3-dimethylpyrazole-4-carboxylic acid Chemical compound CC1=NN(C)C(OC=2C=C(C)C=C(C)C=2)=C1C(O)=O HYDZFUQIPPQKIR-UHFFFAOYSA-N 0.000 description 1
- DYBQXZCMWRGUMZ-UHFFFAOYSA-N 5-(3-chloro-5-fluorophenoxy)-1,3-dimethylpyrazole-4-carboxylic acid Chemical compound CC1=NN(C)C(OC=2C=C(Cl)C=C(F)C=2)=C1C(O)=O DYBQXZCMWRGUMZ-UHFFFAOYSA-N 0.000 description 1
- GUZQYDFNVLHCFL-UHFFFAOYSA-N 5-(3-chlorophenoxy)-1,3-dimethylpyrazole-4-carboxylic acid Chemical compound CC1=NN(C)C(OC=2C=C(Cl)C=CC=2)=C1C(O)=O GUZQYDFNVLHCFL-UHFFFAOYSA-N 0.000 description 1
- IUBXHQJAWYBEDN-UHFFFAOYSA-N 5-(4-chlorophenoxy)-1,3-dimethylpyrazole-4-carboxylic acid Chemical compound CC1=NN(C)C(OC=2C=CC(Cl)=CC=2)=C1C(O)=O IUBXHQJAWYBEDN-UHFFFAOYSA-N 0.000 description 1
- KVOXMVMYDDSCNU-UHFFFAOYSA-N 5-[3-(difluoromethyl)phenoxy]-1-methyl-3-(trifluoromethyl)pyrazole-4-carboxylic acid Chemical compound CN1N=C(C(F)(F)F)C(C(O)=O)=C1OC1=CC=CC(C(F)F)=C1 KVOXMVMYDDSCNU-UHFFFAOYSA-N 0.000 description 1
- DCPAJKKIWRCKIA-UHFFFAOYSA-N 5-[3-(trifluoromethyl)phenoxy]-1H-pyrazole-4-carboxylic acid Chemical compound FC(C=1C=C(OC2=NNC=C2C(=O)O)C=CC1)(F)F DCPAJKKIWRCKIA-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010048961 Localised oedema Diseases 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 208000007156 Spondylarthritis Diseases 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- GPDHNZNLPKYHCN-DZOOLQPHSA-N [[(z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-morpholin-4-ylmethylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CCOC(=O)C(\C#N)=N/OC(=[N+](C)C)N1CCOCC1 GPDHNZNLPKYHCN-DZOOLQPHSA-N 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000011496 cAMP-mediated signaling Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- HFNQLYDPNAZRCH-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O.OC(O)=O HFNQLYDPNAZRCH-UHFFFAOYSA-N 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- QCJQWSQYBVSEAZ-UHFFFAOYSA-N dimethyl(morpholin-4-ylmethylidene)azanium Chemical compound CN(C)[CH+]N1CCOCC1 QCJQWSQYBVSEAZ-UHFFFAOYSA-N 0.000 description 1
- 238000011549 displacement method Methods 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 108700016226 indium-bleomycin Proteins 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000024949 interleukin-17 production Effects 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- JUMQWXLIAYMPHT-UHFFFAOYSA-N methyl 4-(1-aminocyclopropyl)benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C1(N)CC1 JUMQWXLIAYMPHT-UHFFFAOYSA-N 0.000 description 1
- XSYGLHLLQZGWPT-ZETCQYMHSA-N methyl 4-[(1s)-1-aminoethyl]benzoate Chemical compound COC(=O)C1=CC=C([C@H](C)N)C=C1 XSYGLHLLQZGWPT-ZETCQYMHSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- TVDHMDXPKGMXRT-UHFFFAOYSA-M sodium;[4-[[4-(5-methoxypyridin-2-yl)phenoxy]methyl]-5-methylfuran-2-carbonyl]-(2-methylphenyl)sulfonylazanide Chemical compound [Na+].N1=CC(OC)=CC=C1C(C=C1)=CC=C1OCC1=C(C)OC(C(=O)[N-]S(=O)(=O)C=2C(=CC=CC=2)C)=C1 TVDHMDXPKGMXRT-UHFFFAOYSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000005500 uronium group Chemical group 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38478110P | 2010-09-21 | 2010-09-21 | |
| US384781P | 2010-09-21 | ||
| PCT/US2011/051163 WO2012039972A1 (en) | 2010-09-21 | 2011-09-12 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2610185T3 true ES2610185T3 (es) | 2017-04-26 |
Family
ID=44674894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11760631.9T Active ES2610185T3 (es) | 2010-09-21 | 2011-09-12 | Composición farmacéutica |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8686018B2 (enExample) |
| EP (2) | EP3061751A1 (enExample) |
| JP (1) | JP5956448B2 (enExample) |
| KR (1) | KR101911105B1 (enExample) |
| CN (1) | CN103097358B (enExample) |
| AU (1) | AU2011305872B2 (enExample) |
| BR (1) | BR112013002484B1 (enExample) |
| CA (1) | CA2806121C (enExample) |
| CL (1) | CL2013000675A1 (enExample) |
| CY (1) | CY1118680T1 (enExample) |
| DK (1) | DK2619182T3 (enExample) |
| ES (1) | ES2610185T3 (enExample) |
| HR (1) | HRP20170042T1 (enExample) |
| HU (1) | HUE031408T2 (enExample) |
| IL (1) | IL224288A (enExample) |
| LT (1) | LT2619182T (enExample) |
| ME (1) | ME02575B (enExample) |
| MX (1) | MX2013003162A (enExample) |
| MY (1) | MY162146A (enExample) |
| NZ (1) | NZ606629A (enExample) |
| PE (1) | PE20131343A1 (enExample) |
| PH (1) | PH12013500467A1 (enExample) |
| PL (1) | PL2619182T3 (enExample) |
| PT (1) | PT2619182T (enExample) |
| RS (1) | RS55566B1 (enExample) |
| RU (1) | RU2606510C2 (enExample) |
| SG (1) | SG188188A1 (enExample) |
| SI (1) | SI2619182T1 (enExample) |
| SM (2) | SMT201700008T1 (enExample) |
| UA (1) | UA113499C2 (enExample) |
| WO (1) | WO2012039972A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3296B1 (ar) * | 2012-06-29 | 2018-09-16 | Lilly Co Eli | مركبات فينوكسي إيثيل بيبريدين |
| WO2014200075A1 (ja) | 2013-06-12 | 2014-12-18 | 科研製薬株式会社 | ４－アルキニルイミダゾール誘導体およびそれを有効成分として含有する医薬 |
| TW201623277A (zh) * | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
| KR102535283B1 (ko) * | 2014-05-23 | 2023-05-22 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 암의 치료를 위한 조합 요법 |
| TWI730959B (zh) | 2015-05-19 | 2021-06-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺 |
| CA2993312A1 (en) | 2015-07-23 | 2017-01-26 | Takeda Pharmaceutical Company Limited | 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists |
| WO2017066633A1 (en) | 2015-10-16 | 2017-04-20 | Eisai R&D Management Co., Ltd. | Ep4 antagonists |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| ES2896476T3 (es) | 2017-05-18 | 2022-02-24 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina |
| US11325899B2 (en) | 2017-05-18 | 2022-05-10 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators |
| AR111808A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| HRP20211533T1 (hr) | 2017-05-18 | 2022-01-07 | Idorsia Pharmaceuticals Ltd | Derivati fenila kao modulatori receptora pge2 |
| TWI768043B (zh) | 2017-05-18 | 2022-06-21 | 瑞士商愛杜西亞製藥有限公司 | N-取代吲哚衍生物 |
| CN108929281B (zh) * | 2017-05-27 | 2021-12-24 | 华东师范大学 | 三氮唑类化合物及其合成方法和应用 |
| AU2019214193B2 (en) * | 2018-02-05 | 2022-06-16 | Foshan Ionova Biotherapeutics Co., Inc. | Heterobicyclic carboxylic acids for treating cancer or inflammatory diseases |
| US20230125494A1 (en) * | 2020-03-04 | 2023-04-27 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | Synthesis of novel ep4 antagonist and use in cancer and inflammation |
| WO2022037601A1 (zh) * | 2020-08-18 | 2022-02-24 | 武汉人福创新药物研发中心有限公司 | 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在制备治疗癌症和炎症药物中的用途 |
| KR20230107228A (ko) | 2020-11-13 | 2023-07-14 | 오노 야꾸힝 고교 가부시키가이샤 | Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료 |
| TWI877433B (zh) | 2020-11-30 | 2025-03-21 | 大陸商杭州阿諾生物醫藥科技有限公司 | 用於治療ｐｉｋ３ｃａ突變癌症的組合療法 |
| CN116801879B (zh) * | 2021-01-28 | 2025-09-26 | 深圳众格生物科技有限公司 | 吡唑酰胺衍生物及其制备方法和应用 |
| CA3230557A1 (en) * | 2021-09-03 | 2023-03-09 | Xuejun Zhang | Ep4 antagonist compound as well as salt, polymorph, and use thereof |
| CN115364222A (zh) * | 2021-09-09 | 2022-11-22 | 首都医科大学附属北京地坛医院 | Ep4受体抑制剂治疗肝纤维化的应用 |
| CN118414328A (zh) | 2021-12-23 | 2024-07-30 | 卫材R&D管理有限公司 | Ep4拮抗剂的结晶盐形式 |
| JP2024544423A (ja) * | 2021-12-30 | 2024-11-29 | 杭州阿諾生物医薬科技有限公司 | 固体医薬組成物 |
| WO2024027599A1 (zh) * | 2022-08-04 | 2024-02-08 | 杭州阿诺生物医药科技有限公司 | 预测直肠癌对an0025联合放疗/放化疗(rt/crt)治疗敏感性的生物标志物 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0421671A (ja) * | 1990-05-16 | 1992-01-24 | Mitsubishi Kasei Corp | ４―ピラゾールカルボキサミド類およびこれを有効成分とする殺虫、殺ダニ剤 |
| IL104311A (en) * | 1992-02-05 | 1997-07-13 | Fujisawa Pharmaceutical Co | Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
| US6211197B1 (en) * | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
| US7119108B1 (en) | 1999-10-18 | 2006-10-10 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
| US7393842B2 (en) | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| TW591020B (en) | 2001-06-20 | 2004-06-11 | Wyeth Corp | 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
| US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| WO2004037212A2 (en) | 2002-10-24 | 2004-05-06 | Sepracor, Inc. | Compositions comprising zopiclone derivatives and methods of making and using the same |
| FR2847160A1 (fr) | 2002-11-20 | 2004-05-21 | Oreal | Composition capillaire contenant un compose pyrasol-carboxamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute |
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| CN1832928B (zh) * | 2003-06-26 | 2012-07-04 | 诺瓦提斯公司 | 以5元杂环为基础的p38激酶抑制剂 |
| EP1663979B1 (en) | 2003-09-03 | 2013-10-09 | RaQualia Pharma Inc. | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists |
| GT200500013A (es) | 2004-01-23 | 2005-08-10 | Amidas herbicidas | |
| AU2005238292A1 (en) * | 2004-05-04 | 2005-11-10 | Pfizer Inc. | Ortho substituted aryl or heteroaryl amide compounds |
| AP2006003785A0 (en) * | 2004-05-04 | 2006-10-31 | Pfizer | Substituted methylaryl or heteroaryl amide compounds |
| TW200716576A (en) | 2005-06-07 | 2007-05-01 | Shionogi & Co | Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| US20090131470A1 (en) * | 2005-06-11 | 2009-05-21 | Vernalis R & D Limited | Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders |
| CN101273013B (zh) * | 2005-09-27 | 2013-06-12 | 盐野义制药株式会社 | 具有pgd2受体拮抗活性的磺酰胺衍生物 |
| KR101024227B1 (ko) | 2005-11-21 | 2011-03-29 | 시오노기세이야쿠가부시키가이샤 | 11-β-히드록시스테로이드 탈수소효소 제 Ⅰ 형에 대한저해 활성을 갖는 헤테로시클릭 화합물 |
| US7994204B2 (en) * | 2006-02-06 | 2011-08-09 | Taisho Pharmaceutical Co., Ltd | Binding inhibitor of sphingosine-1-phosphate |
| WO2007143825A1 (en) | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Indoline amide derivatives as ep4 receptor ligands |
| CN101541778B (zh) | 2006-08-11 | 2014-10-08 | 默克加拿大有限公司 | 作为ep4受体配体的噻吩甲酰胺衍生物 |
| CA2672631A1 (en) | 2006-12-15 | 2008-06-19 | Glaxo Group Limited | Benzamide derivatives as ep4 receptor agonists |
| EP2114877B1 (en) | 2007-02-26 | 2012-12-26 | Merck Canada Inc. | Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists |
| US7560936B1 (en) | 2007-04-24 | 2009-07-14 | Integrated Device Technology, Inc. | Method and apparatus for ground bounce and power supply bounce detection |
| WO2008152138A2 (de) | 2007-06-15 | 2008-12-18 | Basf Se | Verfahren zur herstellung difluormethylsubstituierter pyrazolverbindungen |
| WO2009005076A1 (ja) * | 2007-07-03 | 2009-01-08 | Astellas Pharma Inc. | アミド化合物 |
| JP2010533736A (ja) * | 2007-07-19 | 2010-10-28 | ハー・ルンドベック・アクチエゼルスカベット | ５員複素環アミドおよび関連化合物 |
| CL2008002241A1 (es) | 2007-07-31 | 2009-12-28 | Bayer Cropscience Sa | Compuestos derivados de (hetero)aril-metilen-n-cicloalquil carboxamida condensados de 6 elementos con n-sustituido; composicion funguicida que comprende uno de dichos compuestos; y metodo para el control hongos fitopatogenos de cultivos agricolas. |
| GB0721611D0 (en) | 2007-11-02 | 2007-12-12 | Glaxo Group Ltd | Novel compounds |
| CA2722811C (en) * | 2008-05-06 | 2016-07-05 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as ccr1 antagonists |
| PL2565191T3 (pl) * | 2008-05-14 | 2015-03-31 | Astellas Pharma Inc | Pochodne kwasu 4-(indol-7-ilokarbonyloaminometylo)cykloheksanokarboksylowego jako antagoniści receptora EP4 użyteczni do leczenia przewlekłej niewydolności nerek lub nefropatii cukrzycowej |
| UA100291C2 (uk) | 2008-08-01 | 2012-12-10 | Байєр Кропсайнс Аг | Фунгіцидні похідні n-циклоалкіл-n-біфенілметилкарбоксаміду |
| CA2733247C (en) * | 2008-08-14 | 2018-04-03 | Beta Pharma Canada Inc. | Heterocyclic amide derivatives as ep4 receptor antagonists |
| WO2010034110A1 (en) | 2008-09-25 | 2010-04-01 | Merck Frosst Canada Ltd. | Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists |
-
2011
- 2011-09-12 KR KR1020137004494A patent/KR101911105B1/ko active Active
- 2011-09-12 EP EP16161460.7A patent/EP3061751A1/en not_active Withdrawn
- 2011-09-12 MY MYPI2013700146A patent/MY162146A/en unknown
- 2011-09-12 ME MEP-2017-3A patent/ME02575B/me unknown
- 2011-09-12 PL PL11760631T patent/PL2619182T3/pl unknown
- 2011-09-12 DK DK11760631.9T patent/DK2619182T3/en active
- 2011-09-12 ES ES11760631.9T patent/ES2610185T3/es active Active
- 2011-09-12 HR HRP20170042TT patent/HRP20170042T1/hr unknown
- 2011-09-12 HU HUE11760631A patent/HUE031408T2/en unknown
- 2011-09-12 SG SG2013007174A patent/SG188188A1/en unknown
- 2011-09-12 NZ NZ60662911A patent/NZ606629A/en unknown
- 2011-09-12 SM SM20170008T patent/SMT201700008T1/it unknown
- 2011-09-12 BR BR112013002484-4A patent/BR112013002484B1/pt active IP Right Grant
- 2011-09-12 CN CN201180045222.XA patent/CN103097358B/zh active Active
- 2011-09-12 UA UAA201304961A patent/UA113499C2/uk unknown
- 2011-09-12 PT PT117606319T patent/PT2619182T/pt unknown
- 2011-09-12 EP EP11760631.9A patent/EP2619182B1/en active Active
- 2011-09-12 WO PCT/US2011/051163 patent/WO2012039972A1/en not_active Ceased
- 2011-09-12 MX MX2013003162A patent/MX2013003162A/es active IP Right Grant
- 2011-09-12 CA CA2806121A patent/CA2806121C/en active Active
- 2011-09-12 RS RS20170008A patent/RS55566B1/sr unknown
- 2011-09-12 SI SI201131067A patent/SI2619182T1/sl unknown
- 2011-09-12 PH PH1/2013/500467A patent/PH12013500467A1/en unknown
- 2011-09-12 AU AU2011305872A patent/AU2011305872B2/en active Active
- 2011-09-12 PE PE2013000320A patent/PE20131343A1/es active IP Right Grant
- 2011-09-12 RU RU2013118209A patent/RU2606510C2/ru active
- 2011-09-12 JP JP2013530177A patent/JP5956448B2/ja active Active
- 2011-09-12 LT LTEP11760631.9T patent/LT2619182T/lt unknown
-
2013
- 2013-01-17 IL IL224288A patent/IL224288A/en active IP Right Grant
- 2013-03-12 CL CL2013000675A patent/CL2013000675A1/es unknown
- 2013-03-12 US US13/795,768 patent/US8686018B2/en active Active
-
2014
- 2014-02-05 US US14/173,170 patent/US9000024B2/en active Active
-
2017
- 2017-01-09 SM SM201700008T patent/SMT201700008B/it unknown
- 2017-01-19 CY CY20171100079T patent/CY1118680T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2610185T3 (es) | Composición farmacéutica | |
| ES2526981T3 (es) | N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje | |
| Lasalle et al. | Topical intestinal aminoimidazole agonists of G-protein-coupled bile acid receptor 1 promote glucagon like peptide-1 secretion and improve glucose tolerance | |
| JP2013506679A (ja) | リゾホスファチジン酸受容体アンタゴニストとしての多環式化合物 | |
| CA2806664A1 (en) | Arylsulfonamide derivatives, compositions, and methods of use | |
| JP2016515536A (ja) | 疾患の治療に有用な複素環化合物 | |
| RS20060035A (sr) | Derivati diaril i arilheteroaril uree kao modulatori receptora 5-ht2a serotonina korisni u profilaksi i lečenju poremećaja u vezi sa njima | |
| HUE028051T2 (hu) | Neprilizin inhibitorok | |
| CN103443098A (zh) | 作为溶血磷脂酸受体的拮抗剂的化合物、组合物及其应用 | |
| KR20110091865A (ko) | ２ｈ-크로멘 화합물 및 그의 유도체 | |
| ES2331153T3 (es) | Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos. | |
| JP2022549601A (ja) | ヘテロアリール血漿カリクレインインヒビター | |
| JP2008530074A (ja) | Ｈｍ７４ａ受容体アゴニストとしてのアントラニル酸誘導体 | |
| JP2018519332A (ja) | 炭酸脱水酵素阻害剤としてのアリールスルホンアミド化合物およびその治療的使用 | |
| WO2014180544A1 (en) | Hydantoine derivatives as cd38 inhibitors | |
| WO2013054338A1 (en) | 2-thio-imidazole derivatives as tgr5 modulators | |
| WO1998057922A1 (fr) | Derives de triphenylmethane et leur utilisation | |
| US10406157B2 (en) | Tetrahydropyridopyrazine modulators of GPR6 | |
| JP2009029750A (ja) | アリールプロパン誘導体を有効成分とする糖化最終産物形成阻害剤 | |
| HK1181765B (en) | Pharmaceutical composition | |
| HK1181765A (en) | Pharmaceutical composition |